PRIMARY STUDY
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Key Findings: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV was able to delay the occurrence and to attenuate the magnitude of dyskinesia in an animal model of PD.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Spain
Year of Pub: 2020
Cannabinoids Studied: Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Dosage: THCV was administered i.p. at 2 mg/kg for two weeks.
Route of Administration: Injection
Link to study
